NASDAQ:CDXS

Codexis Stock Forecast, Price & News

$22.89
-0.31 (-1.34 %)
(As of 04/20/2021 12:00 AM ET)
Add
Compare
Today's Range
$21.98
Now: $22.89
$23.19
50-Day Range
$18.08
MA: $22.20
$25.46
52-Week Range
$10.28
Now: $22.89
$29.56
Volume299,312 shs
Average Volume692,417 shs
Market Capitalization$1.47 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.17
Codexis, Inc. discovers, develops, and sells biocatalysts. It offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations. The company's platform is used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. Its platform also enhances the pharmaceuticals companies manufacturing productivity and efficiency or outsourcing the manufacture of the intermediates and active pharmaceutical ingredients. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. Codexis, Inc. was founded in 2002 and is headquartered in Redwood City, California.
Codexis logo

Industry, Sector and Symbol

Industry Industrial organic chemicals
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:CDXS
CUSIP19200510
Phone650-421-8100
Employees181
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$68.46 million
Book Value$1.80 per share

Profitability

Net Income$-11,940,000.00

Miscellaneous

Market Cap$1.47 billion
Next Earnings Date5/6/2021 (Estimated)
OptionableOptionable

Headlines

Codexis (NASDAQ:CDXS) Shares Gap Down to $23.20
April 20, 2021 |  americanbankingnews.com
Codexis (NASDAQ:CDXS) Now Covered by Analysts at Piper Sandler
April 19, 2021 |  americanbankingnews.com
Codexis (NASDAQ:CDXS) Shares Gap Up to $24.00
April 12, 2021 |  americanbankingnews.com
Codexis (NASDAQ:CDXS) Sees Unusually-High Trading Volume
April 1, 2021 |  americanbankingnews.com
CDXS Apr 2021 22.500 call
March 22, 2021 |  ca.finance.yahoo.com
See More Headlines

MarketRank

Overall MarketRank

1.33 out of 5 stars

Medical Sector

761st out of 2,018 stocks

Industrial Organic Chemicals Industry

15th out of 38 stocks

Analyst Opinion: 2.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
$22.89
-0.31 (-1.34 %)
(As of 04/20/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CDXS News and Ratings via Email

Sign-up to receive the latest news and ratings for CDXS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Codexis (NASDAQ:CDXS) Frequently Asked Questions

Is Codexis a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Codexis in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Codexis stock.
View analyst ratings for Codexis
or view top-rated stocks.

What stocks does MarketBeat like better than Codexis?

Wall Street analysts have given Codexis a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Codexis wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Codexis' next earnings date?

Codexis is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Codexis
.

How were Codexis' earnings last quarter?

Codexis, Inc. (NASDAQ:CDXS) announced its earnings results on Thursday, February, 25th. The biotechnology company reported ($0.06) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.13) by $0.07. The biotechnology company earned $21.03 million during the quarter, compared to analyst estimates of $20.36 million. Codexis had a negative trailing twelve-month return on equity of 21.25% and a negative net margin of 31.08%.
View Codexis' earnings history
.

How has Codexis' stock price been impacted by COVID-19?

Codexis' stock was trading at $10.12 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CDXS stock has increased by 126.2% and is now trading at $22.89.
View which stocks have been most impacted by COVID-19
.

What guidance has Codexis issued on next quarter's earnings?

Codexis issued an update on its FY 2021 After-Hours earnings guidance on Thursday, February, 25th. The company provided EPS guidance of for the period. The company issued revenue guidance of $82-85 million, compared to the consensus revenue estimate of $80.53 million.

What price target have analysts set for CDXS?

5 brokerages have issued 12 month target prices for Codexis' shares. Their forecasts range from $16.00 to $32.00. On average, they anticipate Codexis' share price to reach $26.60 in the next year. This suggests a possible upside of 16.2% from the stock's current price.
View analysts' price targets for Codexis
or view top-rated stocks among Wall Street analysts.

Who are Codexis' key executives?

Codexis' management team includes the following people:
  • Mr. John J. Nicols, Pres, CEO & Director (Age 57, Pay $1.06M)
  • Mr. Ross Taylor Jr., M.B.A., Sr. VP & CFO (Age 58, Pay $471.53k)
  • Dr. Karl A. Schoene Ph.D., Sr. VP of Devel. & Operations
  • Dr. Gjalt Huisman Ph.D., Sr. VP of Strategic Devel. & GM of Biotherapeutics
  • Mr. Rob Wilson Ph.D., Sr. VP & GM of Performance Enzymes
  • Dr. Stefan Lutz Ph.D., Sr. VP of Research
  • Mr. Robert Sato M.B.A., Ph.D., Sr. VP of Pharmaceutical Devel., Quality & Regulatory
  • Prof. Gerhard N. Mayr, Special Advisor to the Board (Age 75)
  • Dr. Davinder Singh Brar, Special Advisor to the Board (Age 69)

What is John J. Nicols' approval rating as Codexis' CEO?

25 employees have rated Codexis CEO John J. Nicols on Glassdoor.com. John J. Nicols has an approval rating of 68% among Codexis' employees.

Who are some of Codexis' key competitors?

What other stocks do shareholders of Codexis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Codexis investors own include Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Micron Technology (MU), (CGC), Enphase Energy (ENPH), Intellia Therapeutics (NTLA), NVIDIA (NVDA), OPKO Health (OPK) and Antares Pharma (ATRS).

What is Codexis' stock symbol?

Codexis trades on the NASDAQ under the ticker symbol "CDXS."

Who are Codexis' major shareholders?

Codexis' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Exchange Traded Concepts LLC (0.18%). Company insiders that own Codexis stock include Bernard J Kelley, Byron L Dorgan, Dennis P Wolf, James Lalonde, John J Nicols, Patrick Y Yang and Thomas R Baruch.
View institutional ownership trends for Codexis
.

Which major investors are buying Codexis stock?

CDXS stock was purchased by a variety of institutional investors in the last quarter, including Exchange Traded Concepts LLC. Company insiders that have bought Codexis stock in the last two years include John J Nicols, and Patrick Y Yang.
View insider buying and selling activity for Codexis
or or view top insider-buying stocks.

How do I buy shares of Codexis?

Shares of CDXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Codexis' stock price today?

One share of CDXS stock can currently be purchased for approximately $22.89.

How much money does Codexis make?

Codexis has a market capitalization of $1.47 billion and generates $68.46 million in revenue each year. The biotechnology company earns $-11,940,000.00 in net income (profit) each year or ($0.21) on an earnings per share basis.

How many employees does Codexis have?

Codexis employs 181 workers across the globe.

What is Codexis' official website?

The official website for Codexis is www.codexis.com.

Where are Codexis' headquarters?

Codexis is headquartered at 200 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063.

How can I contact Codexis?

Codexis' mailing address is 200 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. The biotechnology company can be reached via phone at 650-421-8100 or via email at [email protected]


This page was last updated on 4/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.